Takeda is staking out a new partnership it hopes will put it out front as new CAR-T drugs angle for a big break into solid tumors.
The pharma company is partnering with the startup Noile-Immune Biotech, which is pursuing what it says is a next-gen approach to CAR-T.
Novartis just scored the pioneering regulatory win in the field, followed closely by Kite Pharma. But these first therapies, which use reengineered T cells extracted from patients to attack hematological malignancies, have been limited in scope. Takeda and Tokyo-based Noile-Immune hope to use new tech developed with researchers at Yamaguchi University to overcome those limitations.
There are no financial details in the statement. Takeda — which has been reorganizing over the past year — is taking an equity stake in the biotech and paying an upfront tech access fee. In return, Takeda has an option on all licensing rights for the pipeline.
“We recognize the enormous potential of next-generation CAR-T cell therapy technology to deliver transformative medicines in oncology, one of our core therapeutic areas,” said Chris Arendt, the head of oncology discovery at Takeda.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.Free Subscription